MedTrace Logo

Greater Occipital Nerve Block for Migraine Prophylaxis

NCT00915473 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 70

Last updated 2014-03-20

Study results available
· View outcomes & findings →

Summary

Migraine is a common neurological condition that can be disabling, particularly if chronic. Greater occipital nerve (GON) block has been utilized for decades for the treatment of migraine in the absence of a single randomized, placebo-controlled trial documenting its effectiveness.

Hypothesis: Greater occipital nerve block reduces the frequency of days with moderate or severe headache in patients with episodic or chronic migraine.

Conditions

  • Migraine Headache

Interventions

DRUG

bupivicaine

2.5 mL 0.5% bupivicaine

DRUG

normal saline

2.75 mL normal saline

DRUG

methylprednisolone

0.5 mL 20 mg methylprednisolone

DRUG

lidocaine

0.25 mL 1% lidocaine

Sponsors & Collaborators

  • National Center for Advancing Translational Sciences (NCATS)

    collaborator NIH

  • Mayo Clinic

    lead OTHER

Principal Investigators

  • David W. Dodick, M.D. · Mayo Clinic

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-06-30
Primary Completion
2013-01-31
Completion
2013-01-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00915473 on ClinicalTrials.gov